RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) is a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. The company currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, as well as three active licensing agreements in China, Pan-Asia and the United States. RegeneRx maintains an extensive worldwide patent portfolio covering all of its products. For more information, visit the company’s website at www.regenerx.com.